More than 25% of low-income families' earnings go toward healthcare costs.
Private healthcare is becoming more expensive for the nearly 180 million American families covered, according to the results of a study published yesterday in a JAMA Internal Medicine research letter.
A cross-sectional study led by Sukruth A. Shashikumar, M.D., a clinical fellow in medicine at Brigham and Women’s Hospital in Boston and Rishi K. Wadhera, M.D., M.P.P., M.Phil., of Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, looked at Medicare Expenditure Panel Survey Data (MEPS) from 2007 to 2019 to gather healthcare cost information from 96,075 privately insured families. The total healthcare spending of a family was calculated using families’ contributions to premiums plus out-of-pocket medical and prescription drug spending. The annual financial medical burden was found by dividing total healthcare spending by family income minus their estimated food costs.
"If we had also accounted for other basic needs when calculating post-subsistence income, such as housing and utilities, we would have found that an even higher percentage of families’ incomes are dedicated to health care costs," Wadera said in an email interview.
Low-income families were classified as having an income of less than 200% of the federal poverty line for a family of four. In 2019, the federal poverty line for a family of four was $25,750, according to the U.S. Department of Health and Human Services, meaning that a family of four must make below $51,500 a year to qualify as low-income.
Researchers found that low-income families’ medical burden increased from 23.5% in 2007 to 26.4% in 2019 with a total spending increase from $3,920 in 2007 to $4,907 in 2019.
Higher-income families’ burden increased from 5.4% in 2007 to 6.5% in 2019 with a total spending increase from $4,071 in 2007 to $5,239 in 2019.
These increases may be from increased drug costs, aging enrollees and insurers' interest in profitability, the authors say in the study.
“Although medical burden increased across all populations, it is most worrisome for low-income families,” Shashikumar and Wadhera write. “Low-income families are disproportionately affected by debt and are more susceptible to adverse health outcomes.”
Shashikumar and Wadhera suggest that policymakers should strengthen income-based subsidies and bolster antitrust laws to combat this.
"Our findings highlight the critical need to develop policy strategies to financially protect low-income families with private health insurance - our finding that >25% of these families' income goes towards healthcare costs is very concerning," Wadera concluded.
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Breast Cancer Patients Desire Early, Frequent Financial Screening
November 11th 2024Current financial screening procedures in the United States may need to change, according to recent research done by Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
The Takeaway From Study of Midlife MS Patients: Don't Stop Disease-Modifying Therapy
Published: November 11th 2024 | Updated: November 11th 2024People with multiple sclerosis (MS) often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop disease-modifying therapy have higher hospitalization rates and more visits to the emergency room.
Read More